Inhibitory Effects of Laminaria japonica Fucoidans Against Noroviruses
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyojin | - |
dc.contributor.author | Lim, Chae Yeon | - |
dc.contributor.author | Lee, Dan Bi | - |
dc.contributor.author | Seok, Jong Hyeon | - |
dc.contributor.author | Kim, Kyung Hyun | - |
dc.contributor.author | Chung, Mi Sook | - |
dc.date.accessioned | 2021-08-30T15:06:54Z | - |
dc.date.available | 2021-08-30T15:06:54Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1999-4915 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53220 | - |
dc.description.abstract | Norovirus is the leading cause of nonbacterial foodborne disease outbreaks. Human noroviruses (HuNoVs) bind to histo-blood group antigens as the host receptor for infection. In this study, the inhibitory effects of fucoidans from brown algae, Laminaria japonica (LJ), Undaria pinnatifida and Undaria pinnatifida sporophyll, were evaluated against murine norovirus (MNoV), feline calicivirus (FCV) and HuNoV. Pretreatment of MNoV or FCV with the fucoidans at 1 mg/mL showed high antiviral activities, with 1.1 average log reductions of viral titers in plaque assays. They also showed significant inhibition on the binding of the P domains of HuNoV GII.4 and GII.17 to A- or O-type saliva and the LJ fucoidan was the most effective, reaching 54-72% inhibition at 1 mg/mL. In STAT1(-/-) mice infected with MNoV, oral administration of the LJ fucoidan, composed of mainly sulfated fucose and minor amounts of glucose and galactose, improved the survival rates of mice and significantly reduced the viral titers in their feces. Overall, these results provide the LJ fucoidan can be used to reduce NoV outbreaks. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | BLOOD GROUP ANTIGENS | - |
dc.subject | SACCHARINA-JAPONICA | - |
dc.subject | STRUCTURAL-ANALYSIS | - |
dc.subject | MURINE NOROVIRUS | - |
dc.subject | NORWALK VIRUS | - |
dc.subject | BINDING | - |
dc.subject | MODEL | - |
dc.subject | REPLICATION | - |
dc.subject | ANTIOXIDANT | - |
dc.subject | EXTRACT | - |
dc.title | Inhibitory Effects of Laminaria japonica Fucoidans Against Noroviruses | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Hyun | - |
dc.identifier.doi | 10.3390/v12090997 | - |
dc.identifier.scopusid | 2-s2.0-85090820876 | - |
dc.identifier.wosid | 000582054000001 | - |
dc.identifier.bibliographicCitation | VIRUSES-BASEL, v.12, no.9 | - |
dc.relation.isPartOf | VIRUSES-BASEL | - |
dc.citation.title | VIRUSES-BASEL | - |
dc.citation.volume | 12 | - |
dc.citation.number | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | BLOOD GROUP ANTIGENS | - |
dc.subject.keywordPlus | SACCHARINA-JAPONICA | - |
dc.subject.keywordPlus | STRUCTURAL-ANALYSIS | - |
dc.subject.keywordPlus | MURINE NOROVIRUS | - |
dc.subject.keywordPlus | NORWALK VIRUS | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordPlus | REPLICATION | - |
dc.subject.keywordPlus | ANTIOXIDANT | - |
dc.subject.keywordPlus | EXTRACT | - |
dc.subject.keywordAuthor | norovirus | - |
dc.subject.keywordAuthor | P domain | - |
dc.subject.keywordAuthor | antiviral | - |
dc.subject.keywordAuthor | Laminaria japonica | - |
dc.subject.keywordAuthor | fucoidan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.